切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2019, Vol. 13 ›› Issue (05) : 396 -401. doi: 10.3877/cma.j.issn.1674-1358.2019.05.009

所属专题: 文献

论著

获得性免疫缺陷综合征合并肺孢子菌性肺炎患者病情影响因素
逄晓莉1, 张哲1, 肖江1, 曾永秦1, 樊立娜1, 汪笛1, 李蓓1, 黄丹1, 韩俊燕2, 郝禹2, 赵红心1,()   
  1. 1. 100015 北京,首都医科大学附属北京地坛医院感染科
    2. 100015 北京,新发突发传染病研究北京市重点实验室
  • 收稿日期:2019-05-15 出版日期:2019-10-15
  • 通信作者: 赵红心
  • 基金资助:
    "十三五"国家科技重大专项(No. 2018ZX10715005-002-001); 国家自然科学基金(No. 81672000)

Influencing factors on the progression of acquired immunodeficiency syndrome patients with Pneumocystis carinii pneumonia

Xiaoli Pang1, Zhe Zhang1, Jiang Xiao1, Yongqin Zeng1, Lina Fan1, Di Wang1, Bei Li1, Dan Huang1, Junyan Han2, Yu Hao2, Hongxin Zhao1,()   

  1. 1. Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
    2. Beijing Key Laboratory for Research on Emerging Infectious Diseases, Beijing 100015, China
  • Received:2019-05-15 Published:2019-10-15
  • Corresponding author: Hongxin Zhao
  • About author:
    Corresponding author: Zhao Hongxin, Email:
引用本文:

逄晓莉, 张哲, 肖江, 曾永秦, 樊立娜, 汪笛, 李蓓, 黄丹, 韩俊燕, 郝禹, 赵红心. 获得性免疫缺陷综合征合并肺孢子菌性肺炎患者病情影响因素[J/OL]. 中华实验和临床感染病杂志(电子版), 2019, 13(05): 396-401.

Xiaoli Pang, Zhe Zhang, Jiang Xiao, Yongqin Zeng, Lina Fan, Di Wang, Bei Li, Dan Huang, Junyan Han, Yu Hao, Hongxin Zhao. Influencing factors on the progression of acquired immunodeficiency syndrome patients with Pneumocystis carinii pneumonia[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(05): 396-401.

目的

探讨获得性免疫缺陷综合征(AIDS)合并肺孢子菌性肺炎(PCP)患者病情的影响因素。

方法

分析2009年1月至2017年9月首都医科大学附属北京地坛医院收治的1 001例AIDS合并PCP患者的临床资料,根据PaO2将患者分为轻度PCP组(PaO2 ≥ 70 mmHg)(543例)和中重度PCP组(PaO2 <70 mmHg)(458例),并采用单因素和多因素Logistic回归方法分析年龄、乳酸脱氢酶(LDH)水平增高、肺部混合感染、低蛋白血症和气胸等因素是否影响AIDS合并PCP患者的病情进展。

结果

轻度PCP组和中重度PCP组患者气胸发生率分别为1.1%(6/543)和7.6%(35/458),差异有统计学意义(χ2 = 27.027、P < 0.001);轻度PCP组和中重度PCP组患者肺部混合感染的发生率分别为86.4%(469/543)和95.0%(435/458),差异有统计学意义(χ2 = 21.027、P < 0.001);轻度PCP组和中重度PCP组患者低蛋白血症发生率分别为29.47%(160/543)和42.58%(195/458),差异有统计学意义(χ2 = 18.658、P < 0.001);轻度PCP组和中重度PCP组患者中LDH ≥ 350 U/L者分别为32.04%(174/543)和61.57%(282/458),差异有统计学意义(χ2 = 87.338、P < 0.001)。单因素回归分析发现年龄≥ 50岁、LDH ≥ 350 U/L、肺部混合感染、低蛋白血症和气胸等因素在轻度和中重度PCP两组患者间差异均有统计学意义(OR = 0.489、95%CI:0.354~0.676、P < 0.001,OR = 0.294、95%CI:0.227~0.382、P < 0.001,OR = 0.335、95%CI:0.206~0.545、P < 0.001,OR = 0.563、95%CI:0.434~0.732、P < 0.001,OR = 0.135、95%CI:0.056~0.324、P < 0.001)。多因素Logistic回归分析发现,引起AIDS合并PCP患者病情加重的独立风险因素为年龄≥ 50岁(OR = 0.410、95%CI:0.288~0.582,P < 0.001)、肺部混合感染(OR = 0.417、95%CI:0.251~0.692,P < 0.001)、LDH ≥ 350 U/L(OR = 0.298、95%CI:0.227~0.392,P < 0.001)、低蛋白血症(OR = 0.685、95%CI:0.516~0.908,P = 0.009)和气胸(OR = 0.172、95%CI:0.070~0.424,P < 0.001)。

结论

年龄≥ 50岁、肺部混合感染、LDH水平过高(≥ 350 U/L)、低蛋白血症和气胸等风险因素均可导致AIDS合并PCP患者病情加重,对相关风险因素进行积极干预可减缓患者疾病进展。

Objective

To investigate the factors influencing the exacerbation of acquired immunodeficiency syndrome (AIDS) patients complicated with carinii pneumocystis pneumonia(PCP).

Methods

From January 2009 to September 2017, data of 1 001 AIDS patients complicated with PCP admitted to Beijing Ditan Hospital, Capital Medical University were collected and analyzed. Patients were divided into 543 patients as mild group (PaO2 ≥ 70 mmHg) and 458 patients as moderate-to-severe group (PaO2 < 70 mmHg) according to the level of PaO2. Univariate and multivariate Logistic regression methods were used to analyze whether factors such as age, increased LDH level, mixed pulmonary infection, hypoproteinemia and pneumothorax affected the disease progress of AIDS patients complicated with PCP.

Results

The incidence of pneumothorax in mild group and moderate-to-severe group were 1.1% (6/543) and 7.6% (35/458), respectively, with significant difference (χ2 = 27.027, P < 0.001). The incidence of mixed pathogens in lungs of patients in mild group and moderate-to-severe group were 86.4% (469/543) and 95.0% (435/458), respectively, with significant difference (χ2 = 21.027, P < 0.001). The incidence of hypoproteinemia in mild group and moderate-to-severe group were 29.47% (160/543) and 42.58% (195/458), respectively, with significant difference (χ2 = 18.658, P < 0.001). In mild group, 174 patients (32.04%) had LDH ≥ 350 U/L, and 282 patients (61.57%) with LDH ≥ 350 U/L in moderate-to-severity group, with no significant difference (χ2 = 87.338, P < 0.001). Univariate regression analysis showed that age ≥ 50 years old (OR = 0.489, 95%CI: 0.354-0.676, P < 0.001), LDH ≥ 350 U/L (OR = 0.294, 95%CI: 0.227-0.382, P < 0.001), mixed pulmonary infection (OR = 0.335, 95%CI: 0.206-0.545, P < 0.001), hypoproteinemia (OR = 0.563, 95%CI: 0.434-0.732, P < 0.001) and pneumothorax (OR = 0.135, 95%CI: 0.056-0.324, P < 0.001) were significantly different between the two groups. Multivariate Logistic regression analysis showed that the independent risk factors causing aggravation were age ≥ 50 years old (OR = 0.410, 95%CI: 0.288-0.582, P < 0.001), mixed pulmonary infection (OR = 0.417, 95%CI: 0.251-0.692, P < 0.001), LDH ≥ 350 U/L (OR = 0.298, 95%CI: 0.227-0.392, P < 0.001), hypoproteinemia (OR = 0.685, 95%CI: 0.516-0.908, P = 0.009), and pneumothorax (OR = 0.172, 95%CI: 0.070-0.424, P < 0.001).

Conclusions

Risk factors such as age ≥ 50 years old, mixed pulmonary infection, high LDH level (≥ 350 U/L), hypoproteinemia and pneumothorax could lead to aggravation of disease of patients with AIDS complicated with PCP. The clinical intervention of relevant risk factors could slow down the progress of disease.

表1 两组AIDS合并PCP患者的基本资料[例(%)]
表2 两组AIDS合并PCP患者的体征和实验室指标
表3 两组AIDS合并PCP患者肺部混合感染[例(%)]
表4 影响AIDS合并PCP患者病情进展的单因素回归变量分析
表5 影响AIDS合并PCP患者病情进展的多因素回归分析
[3]
Siegel M,Masur H,Kovacs J. Pneumocystis jirovecii Pneumonia in human immunodeficiency virus infection[J]. Semin Respir Crit Care Med,2016,37(2):243-256.
[4]
Krajicek BJ,Thomas CF,Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment[J]. Clin Chest Med,2009,30(2):265-278.
[5]
Schmiedel Y,Zimmerli S. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia[J]. Swiss Med Wkly,2016,146:w14281.
[6]
Morrow BM,Hsaio NY,Zampoli M, et al. Pneumocystis pneumonia in South African children with and without human immunodeficiency virus infection in the era of highly active antiretroviral therapy[J]. Pediatr Infect Dis J,2010,29(6):535-539.
[7]
李太生. 对获得性免疫缺陷综合征主要机会性感染的认识[J]. 内科理论与实践,2006,1(1):20-22.
[8]
施毅,史家欣. 肺真菌病的临床诊断与实验室检查进展[J]. 临床检验杂志,2017,35(10):725-728.
[9]
中华医学会感染病分会艾滋病丙型肝炎学组,中国疾病预防控制中心. 中国艾滋病诊疗指南(2018版)[J]. 中国艾滋病性病,2018,24(12):1266-1282.
[10]
Salzer HJ,Schafer G,Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia[J]. Respiration,2018,96(1):52-65.
[11]
Mirani G,Williams PL,Chernoff M, et al. Changing Trends in complications and mortality rates among US youth and young adults with HIV infection in the era of combination antiretroviral therapy[J]. Clin Infect Dis,2015,61(12):1850-1861.
[12]
Huang L,Morris A,Crothers K. Pulmonary complications of HIV infection[J]. Semin Respir Crit Care Med,2016,37(2):145-146.
[13]
曾静,刘雪梅,画伟, 等. 艾滋病肺部机会性感染[J]. 中国医药导报,2018,15(4):31-34.
[14]
Manzardo C,Guardo AC,Letang E, et al. Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review[J]. Expert Rev Anti Infect Ther,2015,13(6):751-767.
[15]
Radhi S,Alexander T,Ukwu M, et al. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003[J]. BMC Infect Dis,2008,8:118
[16]
Mayaphi SH,Brauer M,Morobadi DM, et al. Cytomegalovirus viral load kinetics in patients with HIV/AIDS admitted to a medical intensive care unit: A case for pre-emptive therapy[J]. PLoS One,2014,9(4):e93702.
[17]
Griffiths P,Baraniak I,Reeves M. The pathogenesis of human cytomegalovirus[J]. J Pathol,2015,235(2):288-297.
[18]
Grønborg HL,Sanne J,Egedal JH, et al. Prevalence and clinical characteristics of CMV coinfection among HIV infected individuals in Guinea-Bissau: A cross-sectional study[J]. Trop Med Int Health,2018,23(8):896-904.
[19]
Chiliza N,Graham M,Wasserman SA. Outcomes of HIV-associated pneumocystis pneumonia at a South African referral hospital[J]. PLoS One,2018,13(8):6-9.
[20]
Wu L,Zhang Z,Wang Y, et al. A model to predict in-hospital mortality in HIV/AIDS patients with Pneumocystis pneumonia in China: The clinical practice in real world[J]. Biomed Res Int,2019,2019:1-11.
[21]
李爱新,黄春洋,张宏伟, 等. 艾滋病合并肺孢子菌性肺炎患者近期预后危险因素分析 [J]. 中华医学杂志,2017,97(11):833-837.
[22]
Sage EKE,Noursadeghi MM,Evans HEH, et al. Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia[J]. Int J STD AIDS,2010,21(4):288-292.
[23]
Liu Y,Su L,Jiang SJ, et al. Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis[J]. Oncotarget,2017,8(35):59729-59739.
[24]
Afessa B. Pleural effusion and pneumothorax in hospitalized patients with HIV infection: the pulmonary complications, ICU support, and prognostic factors of hospitalized patients with HIV (PIP) study[J]. Chest,2000,117(4):1031-1037.
[25]
Solano LMF,Alvarez LF,Grau S, et al. Pneumocystis jiroveci pneumonia: Clinical characteristics and mortality risk factors in an Intensive Care Unit[J]. Med Intensiva,2015,39(1):13-19.
[26]
Hoshino A,Imai K,Ohshima Y, et al. Pneumothorax in patients with severe combined immunodeficiency[J]. Pediatr Int,2014,56(4):510-514.
[1]
Rali P,Veer M,Gupta N, et al. Opportunistic pulmonary infections in immunocompromised hosts[J]. Crit Care Nurs Q,2016,39(2):161-75.
[2]
Limper AH,Adenis A,Le T, et al. Fungal infections in HIV/AIDS[J]. Lancet Infect Dis,2017,17(11):e334-e343.
[27]
Sage EK,Noursadeghi M,Evans HE, et al. Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia[J]. Int J STD AIDS,2010,21(4):288-292.
[28]
Kageyama T,Furuta S,Ikeda K, et al. Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune diseases[J]. PLoS One,2019,14(3):214-324.
[1] 郑宝英, 黄小兰, 贾楠, 朱春梅. 儿童难治性肺炎支原体肺炎早期预警指标[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(04): 215-221.
[2] 张超, 张珍, 马梁, 穆欢欢, 刘彩玲. 腹腔镜胰十二指肠切除术术后C级胰瘘患者临床特征及影响因素研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 675-678.
[3] 韩婧, 郝少龙, 康骅. 北京市单中心甲状腺癌患者临床特征的回顾分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 490-493.
[4] 寇宛婷, 蔡英华, 周海琴, 吴琼. 肺移植术后谵妄影响因素的范围综述[J/OL]. 中华移植杂志(电子版), 2024, 18(04): 251-256.
[5] 刘璐璐, 何羽. 慢性阻塞性肺病患者睡眠障碍的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 836-839.
[6] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[7] 陈宗杰, 胡添松. 肝外伤破裂患者治疗后胆漏发生影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 836-840.
[8] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[9] 何慧玲, 鲁祖斌, 冯嘉莉, 梁声强. 术前外周血NLR和PLR对结肠癌术后肝转移的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 682-687.
[10] 王贝贝, 崔振义, 王静, 王晗妍, 吕红芝, 李秀婷. 老年股骨粗隆间骨折患者术后贫血预测模型的构建与验证[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 355-362.
[11] 房桂彬, 肖进, 傅光涛, 郑秋坚. 老年髋部骨折患者术后1年行走能力的影响因素分析[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(05): 273-280.
[12] 单良, 刘怡, 于涛, 徐丽. 老年股骨颈骨折术后患者心理弹性现状及影响因素分析[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(05): 294-300.
[13] 王如海, 王绅, 张敏, 李春, 韩超, 于强, 胡海成, 李习珍. 重型创伤性脑损伤患者去骨瓣减压术后短期死亡风险的影响因素分析[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 285-291.
[14] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
[15] 黄晓云, 姚雅极. 院前急救医师职业寿命影响因素与对策思考[J/OL]. 中华卫生应急电子杂志, 2024, 10(05): 281-285.
阅读次数
全文


摘要